View ValuationPaxman 향후 성장Future 기준 점검 6/6Paxman (는) 각각 연간 57.2% 및 30.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 57.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 41.8% 로 예상됩니다.핵심 정보57.2%이익 성장률57.32%EPS 성장률Medical Equipment 이익 성장16.4%매출 성장률30.1%향후 자기자본이익률41.75%애널리스트 커버리지Low마지막 업데이트26 Feb 2024최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 23+ 1 more updatePaxman AB (publ) to Report First Half, 2026 Results on Aug 21, 2026Paxman AB (publ) announced that they will report first half, 2026 results on Aug 21, 2026공시 • May 20Paxman AB (publ) to Report Q1, 2026 Results on May 21, 2026Paxman AB (publ) announced that they will report Q1, 2026 results at 7:00 AM, Central European Standard Time on May 21, 2026공시 • Apr 21Paxman AB (publ), Annual General Meeting, May 22, 2026Paxman AB (publ), Annual General Meeting, May 22, 2026, at 10:00 W. Europe Standard Time. Location: minnesota conference venue, pirgatan 6, 374 35 karlshamn, sweden, Sweden공시 • Feb 23Paxman AB (publ) to Report Fiscal Year 2025 Results on Feb 27, 2026Paxman AB (publ) announced that they will report fiscal year 2025 results at 7:00 AM, Central European Standard Time on Feb 27, 2026공시 • Feb 21Paxman Announces Category III CPT Codes for Cryocompression Therapy to Prevent Chemotherapy-Induced Peripheral NeuropathyPaxman announced that the American Medical Association (AMA) CPT Editorial Panel has established three Category III CPT®? codes describing the use of the Paxman Cryocompression Device for the prevention of chemotherapy-induced peripheral neuropathy (CIPN) in hands and feet. Taking effect January 1, 2027, the new Category III codes establish a standardized reporting pathway for mechanical extremity cryocompression therapy delivered in conjunction with neurotoxic chemotherapy: The three-code structure mirrors the established coding framework for Paxman's FDA-cleared scalp cooling system, supporting structured reporting, data collection, and payer engagement. During chemotherapy infusion, The Paxman Neuropathy System combines consistent cooling and dynamic compression to the hands and feet to reduce the incidence and severity of CIPN - a common side effect of widely used chemotherapies such as paclitaxel and docetaxel, that can significantly impair patients' quality of life. In October, The Paxman Neuropathy system was accepted into the U.S. Food and Drug Administration Safer Technologies Program (STeP), a voluntary program designed to facilitate development and review of medical devices expected to improve safety outcomes. The device is currently under substantive review by the FDA. Product launches in select markets are planned for 2026, with launch to all markets anticipated in 2027. Clinical development of The Paxman Neuropathy System is supported by strong and expanding evidence, including ongoing clinical trials conducted by the SWOG Cancer Research Network, Dana-Farber Cancer Institute, and the National University Hospital Singapore. Together, these studies are contributing to a growing global evidence base evaluating the safety and effectiveness of cryocompression therapy in preventing CIPN.공시 • Jan 02Paxman Announces 510k Submission to the U.S. Food and Drug Administration for the Paxman Cryocompression Device to Prevent Chemotherapy-Induced Peripheral NeuropathyPAXMAN announced that the U.S. Food and Drug Administration (FDA) has confirmed receipt of the 510k Submission for the Paxman cryocompression device to prevent chemotherapy-induced peripheral neuropathy (CIPN). A 510(k) is a premarket submission made to FDA to demonstrate that the device to be marketed is as safe and effective. This follows the news in October, that the Paxman device, was accepted into the US FDA's Safer Technologies Program (STeP), and additionally, confirmation that the Category III CPT Code Application for the device, submitted to the American Medical Association (AMA) in November, is to be included on the Proposed Agenda for the February 2026 CPT®? Editorial Panel Meeting. These steps mark significant milestones in Paxman's regulatory pathways towards FDA clearance of this new technology. Product launches in select markets are currently being planned for 2026 with launch to all markets anticipated in 2027. More information regarding timelines will be communicated in the New Year.공시 • Oct 20PAXMAN Announces Acceptance of Paxman Limb Cryocompression System (PLCS) into the FDA's Safer Technologies ProgramPAXMAN announced that the U.S. Food and Drug Administration (FDA) has accepted the Paxman Limb Cryocompression System (PLCS) into the FDA's Safer Technologies Program (STeP). The FDA's Safer Technologies Program ("STeP") is a voluntary initiative designed to accelerate the development and clearance of medical devices that have the potential to reduce known risks associated with current treatments for non-life threatening conditions. Paxman submitted the STeP Designation Request Q240974/S002 in August 2025. Confirmation that the PLCS meets the eligibility factors for STeP is a significant milestone in Paxman's regulatory pathways towards FDA clearance of this new technology. Chemotherapy-induced peripheral neuropathy (CIPN) is a severe dose-limiting toxicity of paclitaxel and docetaxel, which are both widely used drugs for the treatment of common cancers including breast, ovarian, endometrial, lung, and gastric cancers. CIPN is an unseen, debilitating, and lifelong condition that severely impacts the quality of life of cancer patients. Acceptance into STeP underscores the innovative potential of the Paxman device to address this important unmet clinical need of reducing the incidence and severity of CIPN in cancer patients receiving systemic neurotoxic chemotherapy or combination therapy.공시 • Apr 17Paxman AB (publ), Annual General Meeting, May 16, 2025Paxman AB (publ), Annual General Meeting, May 16, 2025, at 10:00 W. Europe Standard Time. Location: at meeting hall zambesi, netport, biblioteksgatan 4, karlshamn, Sweden공시 • Apr 08Paxman AB (Publ) Elects Peter Mattisson as ChairmanPaxman AB (publ) announced that Company held its Extra General Meeting on 8 April 2025 in Karlshamn. At the meeting, Peter Mattisson was elected Chairman.공시 • Mar 22Paxman AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 123.5 million.Paxman AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 123.5 million. Security Name: Shares Security Type: Common Stock Securities Offered: 1,900,000 Price\Range: SEK 65 Transaction Features: Subsequent Direct Listing공시 • Mar 21Paxman AB (publ) has filed a Follow-on Equity Offering.Paxman AB (publ) has filed a Follow-on Equity Offering. Security Name: Shares Security Type: Common Stock Securities Offered: 1,900,000 Transaction Features: Subsequent Direct Listing공시 • Mar 19Paxman AB (publ) (OM:PAX) proposed to acquire Dignitana AB (publ) (OM:DIGN) from Agartha AB, UBS Financial Services Inc and others for Approximately SEK 150 million.Paxman AB (publ) (OM:PAX) proposed to acquire Dignitana AB (publ) (OM:DIGN) from Agartha AB, UBS Financial Services Inc. and others for Approximately SEK 150 million on March 18, 2025. As part of acquisition, Paxman AB will acquire all shares in Dignitana AB. As part of consideration, Paxman AB will issue 2.5 million newly issued shares at a ratio of 0.030744 per common equity of Dignitana AB (publ). The merger between Paxman and Dignitana creates a New Group which provides clear synergies through increased revenues and reduced costs through rationalization but also economies of scale. Upon completion of the Offer, the shareholders of Paxman will own approximately 88.5% of the votes and capital and the shareholders of Dignitana will own approximately 11.5% of the votes and capital of the New Group. Agartha AB, which controls approximately 29.8% of the total number of outstanding shares and votes in Dignitana, supports and has undertaken to accept the Offer. The acceptance period for the Offer is expected to commence on or around April 14, 2025 and end on or around May 5, 2025, with payment of consideration expected to be made on or around May 13, 2025. In the event that Paxman, in connection with the Offer or otherwise, becomes the owner of shares corresponding to more than 90% of the shares in Dignitana, Paxman intends to call for compulsory acquisition in accordance with the Swedish Companies Act (2005:551) in order to acquire all outstanding shares in Dignitana. In connection therewith, Paxman intends to promote the delisting of Dignitana's shares from Nasdaq First North. The transaction is subject to Offer being accepted to the extent that Paxman becomes the owner of the equivalent of more than 90% of all outstanding shares in Dignitana, approval of the shareholders of Paxman at the extraordinary general meeting of Paxman AB, all necessary authorizations, approvals, decisions and other measures for the Offer and the acquisition of Dignitana are obtained on terms acceptable to Paxman, including approvals from the Inspectorate of Strategic Products and the corresponding authorities in the United Kingdom and Italy. The Offer has been preceded by Paxman conducting a limited due diligence review of Dignitana of a confirmatory nature. The expected completion of the transaction is May 5, 2025. Advokatfirman Delphi KB acted as legal advisor to Paxman AB. Bergs Securities AB acted as financial advisor and issuing agent to Paxman AB. Advokatfirman Vinge KB act as legal advisor to Dignitana AB. Stockholm Corporate Finance AB act as financial advisor to Dignitana AB.공시 • Feb 21+ 3 more updatesPaxman AB (publ) to Report Nine Months, 2025 Results on Nov 14, 2025Paxman AB (publ) announced that they will report nine months, 2025 results on Nov 14, 2025공시 • May 24Paxman AB (publ) Appoints Karen Giddings Clakely to the BoardPAXMAN´s AGM held on 23 May 2024, appointed Karen Giddings Clakely to the board.공시 • Aug 31+ 4 more updatesPaxman AB (publ) to Report First Half, 2024 Results on Aug 21, 2024Paxman AB (publ) announced that they will report first half, 2024 results on Aug 21, 2024공시 • Jan 04Paxman AB (publ) to Report Fiscal Year 2022 Results on May 04, 2023Paxman AB (publ) announced that they will report fiscal year 2022 results on May 04, 2023이익 및 매출 성장 예측OTCPK:PXMB.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (SEK Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202653712376102112/31/2025401845578112/31/202429234315013/31/202423624128N/A12/31/20232218-1016N/A9/30/20232081-288N/A6/30/2023188-2-315N/A3/31/2023173-7-384N/A12/31/2022157-10-333N/A9/30/2022143-2-204N/A6/30/2022125-12-168N/A3/31/2022111-18-27-3N/A12/31/2021105-13-28-4N/A9/30/202193-23-14-7N/A6/30/202187-21-19-12N/A3/31/202180-22-16-9N/A12/31/202083-19-15-8N/A9/30/202090-6-22-1N/A6/30/202096-1-182N/A3/31/20201026-152N/A12/31/2019963-183N/A9/30/201990-4-7-1N/A6/30/201983-5-190N/A3/31/201975-6-182N/A12/31/201869-7-180N/A9/30/201858-9-241N/A6/30/201850-10-20-7N/A3/31/201843-9-25-8N/A12/31/201736-7N/A-7N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: PXMB.F 의 연간 예상 수익 증가율(57.2%)이 saving rate(2.5%)보다 높습니다.수익 vs 시장: PXMB.F 의 연간 수익(57.2%)이 US 시장(18.6%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: PXMB.F 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: PXMB.F 의 수익(연간 30.1%)이 US 시장(연간 12.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: PXMB.F 의 수익(연간 30.1%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: PXMB.F의 자본 수익률은 3년 후 41.8%로 매우 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/08/13 21:18종가2024/05/16 00:00수익2024/03/31연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Paxman AB (publ)는 3명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Maria Karlsson OsipovaDNB Carnegie Commissioned ResearchLudvig SvenssonDNB Carnegie Commissioned ResearchGustaf MeyerRedeye
공시 • May 23+ 1 more updatePaxman AB (publ) to Report First Half, 2026 Results on Aug 21, 2026Paxman AB (publ) announced that they will report first half, 2026 results on Aug 21, 2026
공시 • May 20Paxman AB (publ) to Report Q1, 2026 Results on May 21, 2026Paxman AB (publ) announced that they will report Q1, 2026 results at 7:00 AM, Central European Standard Time on May 21, 2026
공시 • Apr 21Paxman AB (publ), Annual General Meeting, May 22, 2026Paxman AB (publ), Annual General Meeting, May 22, 2026, at 10:00 W. Europe Standard Time. Location: minnesota conference venue, pirgatan 6, 374 35 karlshamn, sweden, Sweden
공시 • Feb 23Paxman AB (publ) to Report Fiscal Year 2025 Results on Feb 27, 2026Paxman AB (publ) announced that they will report fiscal year 2025 results at 7:00 AM, Central European Standard Time on Feb 27, 2026
공시 • Feb 21Paxman Announces Category III CPT Codes for Cryocompression Therapy to Prevent Chemotherapy-Induced Peripheral NeuropathyPaxman announced that the American Medical Association (AMA) CPT Editorial Panel has established three Category III CPT®? codes describing the use of the Paxman Cryocompression Device for the prevention of chemotherapy-induced peripheral neuropathy (CIPN) in hands and feet. Taking effect January 1, 2027, the new Category III codes establish a standardized reporting pathway for mechanical extremity cryocompression therapy delivered in conjunction with neurotoxic chemotherapy: The three-code structure mirrors the established coding framework for Paxman's FDA-cleared scalp cooling system, supporting structured reporting, data collection, and payer engagement. During chemotherapy infusion, The Paxman Neuropathy System combines consistent cooling and dynamic compression to the hands and feet to reduce the incidence and severity of CIPN - a common side effect of widely used chemotherapies such as paclitaxel and docetaxel, that can significantly impair patients' quality of life. In October, The Paxman Neuropathy system was accepted into the U.S. Food and Drug Administration Safer Technologies Program (STeP), a voluntary program designed to facilitate development and review of medical devices expected to improve safety outcomes. The device is currently under substantive review by the FDA. Product launches in select markets are planned for 2026, with launch to all markets anticipated in 2027. Clinical development of The Paxman Neuropathy System is supported by strong and expanding evidence, including ongoing clinical trials conducted by the SWOG Cancer Research Network, Dana-Farber Cancer Institute, and the National University Hospital Singapore. Together, these studies are contributing to a growing global evidence base evaluating the safety and effectiveness of cryocompression therapy in preventing CIPN.
공시 • Jan 02Paxman Announces 510k Submission to the U.S. Food and Drug Administration for the Paxman Cryocompression Device to Prevent Chemotherapy-Induced Peripheral NeuropathyPAXMAN announced that the U.S. Food and Drug Administration (FDA) has confirmed receipt of the 510k Submission for the Paxman cryocompression device to prevent chemotherapy-induced peripheral neuropathy (CIPN). A 510(k) is a premarket submission made to FDA to demonstrate that the device to be marketed is as safe and effective. This follows the news in October, that the Paxman device, was accepted into the US FDA's Safer Technologies Program (STeP), and additionally, confirmation that the Category III CPT Code Application for the device, submitted to the American Medical Association (AMA) in November, is to be included on the Proposed Agenda for the February 2026 CPT®? Editorial Panel Meeting. These steps mark significant milestones in Paxman's regulatory pathways towards FDA clearance of this new technology. Product launches in select markets are currently being planned for 2026 with launch to all markets anticipated in 2027. More information regarding timelines will be communicated in the New Year.
공시 • Oct 20PAXMAN Announces Acceptance of Paxman Limb Cryocompression System (PLCS) into the FDA's Safer Technologies ProgramPAXMAN announced that the U.S. Food and Drug Administration (FDA) has accepted the Paxman Limb Cryocompression System (PLCS) into the FDA's Safer Technologies Program (STeP). The FDA's Safer Technologies Program ("STeP") is a voluntary initiative designed to accelerate the development and clearance of medical devices that have the potential to reduce known risks associated with current treatments for non-life threatening conditions. Paxman submitted the STeP Designation Request Q240974/S002 in August 2025. Confirmation that the PLCS meets the eligibility factors for STeP is a significant milestone in Paxman's regulatory pathways towards FDA clearance of this new technology. Chemotherapy-induced peripheral neuropathy (CIPN) is a severe dose-limiting toxicity of paclitaxel and docetaxel, which are both widely used drugs for the treatment of common cancers including breast, ovarian, endometrial, lung, and gastric cancers. CIPN is an unseen, debilitating, and lifelong condition that severely impacts the quality of life of cancer patients. Acceptance into STeP underscores the innovative potential of the Paxman device to address this important unmet clinical need of reducing the incidence and severity of CIPN in cancer patients receiving systemic neurotoxic chemotherapy or combination therapy.
공시 • Apr 17Paxman AB (publ), Annual General Meeting, May 16, 2025Paxman AB (publ), Annual General Meeting, May 16, 2025, at 10:00 W. Europe Standard Time. Location: at meeting hall zambesi, netport, biblioteksgatan 4, karlshamn, Sweden
공시 • Apr 08Paxman AB (Publ) Elects Peter Mattisson as ChairmanPaxman AB (publ) announced that Company held its Extra General Meeting on 8 April 2025 in Karlshamn. At the meeting, Peter Mattisson was elected Chairman.
공시 • Mar 22Paxman AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 123.5 million.Paxman AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 123.5 million. Security Name: Shares Security Type: Common Stock Securities Offered: 1,900,000 Price\Range: SEK 65 Transaction Features: Subsequent Direct Listing
공시 • Mar 21Paxman AB (publ) has filed a Follow-on Equity Offering.Paxman AB (publ) has filed a Follow-on Equity Offering. Security Name: Shares Security Type: Common Stock Securities Offered: 1,900,000 Transaction Features: Subsequent Direct Listing
공시 • Mar 19Paxman AB (publ) (OM:PAX) proposed to acquire Dignitana AB (publ) (OM:DIGN) from Agartha AB, UBS Financial Services Inc and others for Approximately SEK 150 million.Paxman AB (publ) (OM:PAX) proposed to acquire Dignitana AB (publ) (OM:DIGN) from Agartha AB, UBS Financial Services Inc. and others for Approximately SEK 150 million on March 18, 2025. As part of acquisition, Paxman AB will acquire all shares in Dignitana AB. As part of consideration, Paxman AB will issue 2.5 million newly issued shares at a ratio of 0.030744 per common equity of Dignitana AB (publ). The merger between Paxman and Dignitana creates a New Group which provides clear synergies through increased revenues and reduced costs through rationalization but also economies of scale. Upon completion of the Offer, the shareholders of Paxman will own approximately 88.5% of the votes and capital and the shareholders of Dignitana will own approximately 11.5% of the votes and capital of the New Group. Agartha AB, which controls approximately 29.8% of the total number of outstanding shares and votes in Dignitana, supports and has undertaken to accept the Offer. The acceptance period for the Offer is expected to commence on or around April 14, 2025 and end on or around May 5, 2025, with payment of consideration expected to be made on or around May 13, 2025. In the event that Paxman, in connection with the Offer or otherwise, becomes the owner of shares corresponding to more than 90% of the shares in Dignitana, Paxman intends to call for compulsory acquisition in accordance with the Swedish Companies Act (2005:551) in order to acquire all outstanding shares in Dignitana. In connection therewith, Paxman intends to promote the delisting of Dignitana's shares from Nasdaq First North. The transaction is subject to Offer being accepted to the extent that Paxman becomes the owner of the equivalent of more than 90% of all outstanding shares in Dignitana, approval of the shareholders of Paxman at the extraordinary general meeting of Paxman AB, all necessary authorizations, approvals, decisions and other measures for the Offer and the acquisition of Dignitana are obtained on terms acceptable to Paxman, including approvals from the Inspectorate of Strategic Products and the corresponding authorities in the United Kingdom and Italy. The Offer has been preceded by Paxman conducting a limited due diligence review of Dignitana of a confirmatory nature. The expected completion of the transaction is May 5, 2025. Advokatfirman Delphi KB acted as legal advisor to Paxman AB. Bergs Securities AB acted as financial advisor and issuing agent to Paxman AB. Advokatfirman Vinge KB act as legal advisor to Dignitana AB. Stockholm Corporate Finance AB act as financial advisor to Dignitana AB.
공시 • Feb 21+ 3 more updatesPaxman AB (publ) to Report Nine Months, 2025 Results on Nov 14, 2025Paxman AB (publ) announced that they will report nine months, 2025 results on Nov 14, 2025
공시 • May 24Paxman AB (publ) Appoints Karen Giddings Clakely to the BoardPAXMAN´s AGM held on 23 May 2024, appointed Karen Giddings Clakely to the board.
공시 • Aug 31+ 4 more updatesPaxman AB (publ) to Report First Half, 2024 Results on Aug 21, 2024Paxman AB (publ) announced that they will report first half, 2024 results on Aug 21, 2024
공시 • Jan 04Paxman AB (publ) to Report Fiscal Year 2022 Results on May 04, 2023Paxman AB (publ) announced that they will report fiscal year 2022 results on May 04, 2023